Make better packaging decisions with the all-new Life Science Packaging Materials Playbook

Download the all-new HCP Life Science Packaging Materials Playbook and find out how to consistently select the optimal packaging style and material for your pharma, medicinal devices. Learn More »

News January 3, 2013

Drug-device combination products show healthy growth

New BCC Research report predicts the global market for these combination products to grow at a nearly 10% CAGR between now and 2017.
Coronary stent

BCC Research’s new technical market research report, “Global Markets For Drug Device Combinations,” says the market for global drug-device combination products, valued at $18.5 billion in 2011, should reach $19 billion in 2012. BCC forecasts total market value to rise $30.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.9%.

The publisher of market research reports and technical publications breaks down the market for drug-device combination products can into five major segments: coronary stents (as shown in the illustration here), photodynamic therapies, antimicrobial catheters, orthopedic applications, and all other segments. The report forecasts the following growth for those segments as follows:

• Coronary stents are expected to have a value of $5.8 billion in 2012 and $8.2 billion in 2017, a CAGR of 7.2%.

• Photodynamic therapies as a segment should total $1.7 billion in 2012 and $2.6 billion in 2017, a CAGR of 8.9%.

• Antimicrobial catheters are expected to total $6.6 billion in 2012 and $11.7 billion in 2017, a CAGR of 12.1%.

• The segment made up of orthopedic applications (cements and bone substitutes) should be valued at $2.8 billion in 2012 and $4.1 billion in 2017, a CAGR of 7.9%.

BCC says, “The combination products industry includes makers of drug-delivery systems, gene therapy systems, personalized medicine drug-device combinations, biological-device combinations, nanotechnology, and certain other products for diagnostic and therapeutic treatments of cardiovascular, metabolic, oncologic, and other disorders.
“Combination products are therapeutic and/or diagnostic products that combine elements of drugs, devices, and/or biological products. An estimated 30% of all new healthcare products under development are ‘combination products’ involving medical devices embedded with pharmaceutical or biologics components. The classic example of a combination product that revolutionized patient care is the drug-eluting coronary stent.”

The report includes the following information to benefit readers:

• Forecast the market size for drug-device combination products in terms of dollar and unit sales

• Classify the market size for drug-device combination products by geographical region in terms of dollar and unit sales

• Highlight the roles played by major stakeholders and players

• Provide an overview of the activities of influential companies

• Examine crucial, innovative breakthroughs by means of a detailed patent analysis.

Published Nov. 2012, the report is available as an electronic PDF for $4,850. It aims to provide value to many industry participants, including the following:

• Drug delivery system makers

• Drug device manufacturers

• End users and distributors

• Academic and research institutions

• Financial institutions.

E-Book Special Report
Total Cost of Ownership
Sign up to receive timely updates from our editors and download this E-Book Special Report to learn how to calculate the true Total Cost of Ownership (TCO) of your life sciences machinery.
Don't miss intelligence crucial to your job and business!
Click on any newsletter to view a sample. Enter your email address below to sign up!
Each newsletter ranges in frequency from once per month to a few times per month at most.

Curated By Logo